14733-77-8Relevant articles and documents
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Page/Page column 104, (2016/11/17)
Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)
Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
-
Page/Page column 312, (2015/11/16)
The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
-
Page/Page column 165, (2012/05/20)
The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
-
Page/Page column 23, (2009/10/01)
The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Benzimidazole derivatives, their preparation and use
-
, (2008/06/13)
A compound having the formula STR1 wherein R 1 is hydrogen, NH 2 or C 1-6 -alkyl which may be branched;X is O, S, NCN;Y is O, S;R 4, R 5, R 6 and R 7 independently of each other are hydrogen, halogen, CF 3, NO 2, NH 2, OH, C 1-6 -alkoxy, C( O)-phenyl or SO 2 NR I R II wherein R I and R II independently are hydrogen or C 1-6 -alkyl;R 11 is hydrogen, halogen, NO 2 or SO 2 NR''R"" wherein R'' and R"" independently are hydrogen or C 1-6 -alkyl;R 13 is hydrogen, halogen, phenyl, CF 3, NO 2 ;R 12 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated;R 14 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated;pharmaceutical compositions thereof,and a method of treating a disease in a mammal, including a human, responsive to opening of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound as first above indicated, are disclosed.